Jasper Therapeutics Inc SEC Filings

Lucas Svetlana, a director of Jasper Therapeutics, Inc. (JSPR), reported purchases on 09/22/2025 of 20,000 shares of voting common stock together with 20,000 warrants in an underwritten public offering at a combined purchase price of $2.43 per share and accompanying warrant. Following the transaction she beneficially owns 20,000 shares. The warrants have an exercise price of $2.92, are exercisable beginning 03/22/2026, and expire 03/22/2030. The Form 4 was signed on behalf of the reporting person by an attorney-in-fact on 09/24/2025.

Jasper Therapeutics director and President/CEO Ron Martell purchased 41,000 shares of voting common stock on 09/22/2025 as part of an underwritten public offering at a combined price of $2.43 per share with an accompanying warrant. Each purchased share was paired with a warrant to buy one additional share at an exercise price of $2.92, exercisable from 03/22/2026 through 03/22/2030.

After the transaction, Mr. Martell directly beneficially owned 74,118 shares of voting common stock. The Form 4 was signed by an attorney-in-fact on 09/24/2025. All information is taken directly from the Form 4 filing.

Jasper Therapeutics director Shizuru Judith Anne purchased 41,000 shares of voting common stock together with accompanying warrants in an underwritten public offering on 09/22/2025 at a combined price of $2.43 per share and warrant. The reported transaction increases her direct beneficial ownership to 156,901 shares after the purchase. The accompanying warrants have a $2.92 exercise price, become exercisable on 03/22/2026 and expire on 03/22/2030.

The filing reports the acquisition as a primary purchase (code P) and notes each share was paired with one warrant in the offering. No other transactions, dispositions, or material changes to indirect ownership are disclosed.

Velan Capital and affiliated Avego entities report a joint Schedule 13D/A disclosing purchases in Jasper Therapeutics, Inc. The filing shows 27,889,950 Shares outstanding after the 2025 Offering. Velan Master directly owns 2,381,915 Shares (~8.5%), Velan Horizon owns 41,152 Shares (~0.1%), and Avego Fund owns 245,328 Shares (~0.9%). Aggregated beneficial ownership attributable to Velan Capital Investment Management LP and related entities is 2,668,395 Shares (~9.6%).

The filing discloses purchases made in a September 19, 2025 underwritten offering at $2.43 per unit, related acquisition costs for each purchaser, receipt of Warrants (Velan Master: 1,193,415; Velan Horizon: 41,152) exercisable after six months at $2.92 for four years, a customary 90-day lock-up with the underwriters, and a 9.99% beneficial ownership blocker on the Warrants.

Jasper Therapeutics, Inc. filed an 8-K reporting a material event that includes an Underwriting Agreement dated September 18, 2025 with TD Securities (USA) LLC and a set of exhibits: forms of pre-funded and common warrants, a legal opinion and consent from Paul Hastings LLP, a press release dated September 18, 2025, and an iXBRL cover page file. The filing also describes a comprehensive review and testing program for manufacturing and clinical supply lots, including robust lot testing, independent blinded testing of returned product samples, stability comparisons, and reviews of patient selection, investigational product handling, and drug delivery details. The form is signed by CFO Herb Cross on September 19, 2025. No offering terms, proceeds, or financial impacts are disclosed in the provided text.

Jasper Therapeutics is offering common stock, pre-funded warrants and common warrants to raise approximately $27.9 million in net proceeds, based on a public offering price of $2.43 per common share with an attached common warrant. The offering includes 12,345,707 common warrants (initial exercise price $2.92) and 675,000 pre-funded warrants. Shares outstanding rise from 16,219,243 to 27,889,950 assuming no warrant exercises. Net tangible book value per share was $1.45 as of June 30, 2025, estimated to increase by $0.39 to $1.84, with dilution of $0.59 per share to new investors. The filing reiterates clinical progress for briquilimab across CSU, CIndU and asthma studies showing rapid, deep responses and a favorable safety profile, but notes an ongoing investigation into two cohorts that showed an atypical absence of UAS7 reduction, with results expected in late 2025.

Jasper Therapeutics is offering common stock, pre‑funded warrants and accompanying common warrants while continuing clinical development of briquilimab, an anti–c‑Kit program in mast‑cell driven diseases. The prospectus reports preliminary Phase 1b/2a data across BEACON (CSU), SPOTLIGHT (CIndU) and an OLE: rapid onset of effect (responses as early as 1 week; complete responses by week 2), UAS7 reductions up to 29 points, dose‑dependent durability (complete responses lasting 4, 6 and 8 weeks at 120mg, 180mg and 240mg), and high cohort response rates (for example, 240mg single dose: 100% complete responses through 8 weeks; combined 240mg/360mg single‑dose cohorts: 8 of 9 (89%) complete responses). Safety is described as favorable with low‑grade, transient c‑Kit related AEs and no reported SAEs in several cohorts. An atypical absence of UAS7 reduction in two cohorts prompted an ongoing investigation including lot testing and site reviews after 10 patients dosed with one lot showed no UAS7 reductions; additional patients and alternative drug supply are being enrolled with results expected in late 2025. The company has 16,219,243 shares outstanding and lists common stock under symbol JSPR and public warrants under JSPRW. The prospectus discloses offering terms, use of proceeds for clinical development, tax and transfer limitations, and numerous risk factors including geopolitical and regulatory risks.

Jasper Therapeutics reported a net loss of $26.7 million for the quarter and $48.0 million for the six months ended June 30, 2025. Cash and cash equivalents were $39.5 million and total assets declined to $46.5 million from $79.9 million at year-end. Research and development spending rose materially to $21.2 million for the quarter (vs. $11.3 million prior year), driving total operating expenses of $27.1 million.

Management concluded substantial doubt exists about the company's ability to continue as a going concern because existing cash is not sufficient to fund operations for at least twelve months. On July 8, 2025 the company implemented a corporate reorganization, reducing headcount by approximately 50% to focus on its briquilimab mast-cell programs, halting enrollment in the asthma study and discontinuing other programs; estimated severance is approximately $1.9 million. Clinical updates show strong preliminary CSU and CIndU responses but an investigation into a drug product lot is underway and may affect select cohorts.